Literature DB >> 18235085

The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome.

Ruben Martinez-Barricarte1, Gaia Pianetti, Ruxandra Gautard, Joachim Misselwitz, Lisa Strain, Veronique Fremeaux-Bacchi, Christine Skerka, Peter F Zipfel, Tim Goodship, Marina Noris, Giuseppe Remuzzi, Santiago Rodriguez de Cordoba.   

Abstract

Mutations in the gene encoding complement factor H (CFH) that alter the C3b/polyanions-binding site in the C-terminal region impair the capacity of factor H to protect host cells. These mutations are also strongly associated with atypical hemolytic uremic syndrome (aHUS). Although most of the aHUS-associated CFH mutations seem "unique" to an individual patient or family, the R1210C mutation has been reported in several unrelated aHUS patients from distinct geographic origins. Five aHUS pedigrees and 7 individual aHUS patients were analyzed to identify potential correlations between the R1210C mutation and clinical phenotype and to characterize the origins of this mutation. The clinical phenotype of aHUS patients carrying the R1210C mutation was heterogeneous. Interestingly, 12 of the 13 affected patients carried at least one additional known genetic risk factor for aHUS. These data are in accord with the 30% penetrance of aHUS in R1210C mutation carriers, as it seems that the presence of other genetic or environmental risk factors significantly contribute to the manifestation and severity of aHUS in these subjects. Genotype analysis of CFH and CFHR3 polymorphisms in the 12 unrelated carriers suggested that the R1210C mutation has a single origin. In conclusion, the R1210C mutation of complement factor H is a prototypical aHUS mutation that is present as a rare polymorphism in geographically separated human populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18235085      PMCID: PMC2391060          DOI: 10.1681/ASN.2007080923

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  25 in total

1.  Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32.

Authors:  Jorge Esparza-Gordillo; Elena Goicoechea de Jorge; Alfonso Buil; Luis Carreras Berges; Margarita López-Trascasa; Pilar Sánchez-Corral; Santiago Rodríguez de Córdoba
Journal:  Hum Mol Genet       Date:  2005-01-20       Impact factor: 6.150

2.  Genetic studies into inherited and sporadic hemolytic uremic syndrome.

Authors:  P Warwicker; T H Goodship; R L Donne; Y Pirson; A Nicholls; R M Ward; P Turnpenny; J A Goodship
Journal:  Kidney Int       Date:  1998-04       Impact factor: 10.612

3.  Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome.

Authors:  Marie-Agnès Dragon-Durey; Chantal Loirat; Sylvie Cloarec; Marie-Alice Macher; Jacques Blouin; Hubert Nivet; Laurence Weiss; Wolf Herman Fridman; Véronique Frémeaux-Bacchi
Journal:  J Am Soc Nephrol       Date:  2004-12-08       Impact factor: 10.121

4.  A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration.

Authors:  Gregory S Hageman; Don H Anderson; Lincoln V Johnson; Lisa S Hancox; Andrew J Taiber; Lisa I Hardisty; Jill L Hageman; Heather A Stockman; James D Borchardt; Karen M Gehrs; Richard J H Smith; Giuliana Silvestri; Stephen R Russell; Caroline C W Klaver; Irene Barbazetto; Stanley Chang; Lawrence A Yannuzzi; Gaetano R Barile; John C Merriam; R Theodore Smith; Adam K Olsh; Julie Bergeron; Jana Zernant; Joanna E Merriam; Bert Gold; Michael Dean; Rando Allikmets
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

5.  Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome.

Authors:  Anna Richards; Elizabeth J Kemp; M Kathryn Liszewski; Judith A Goodship; Anne K Lampe; Ronny Decorte; M Hamza Müslümanoğlu; Salih Kavukcu; Guido Filler; Yves Pirson; Leana S Wen; John P Atkinson; Timothy H J Goodship
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-17       Impact factor: 11.205

6.  Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in factor H.

Authors:  P Sánchez-Corral; C González-Rubio; S Rodríguez de Córdoba; M López-Trascasa
Journal:  Mol Immunol       Date:  2004-05       Impact factor: 4.407

7.  Haemolytic uraemic syndrome and mutations of the factor H gene: a registry-based study of German speaking countries.

Authors:  H P H Neumann; M Salzmann; B Bohnert-Iwan; T Mannuelian; C Skerka; D Lenk; B U Bender; M Cybulla; P Riegler; A Königsrainer; U Neyer; A Bock; U Widmer; D A Male; G Franke; P F Zipfel
Journal:  J Med Genet       Date:  2003-09       Impact factor: 6.318

8.  Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome.

Authors:  V Fremeaux-Bacchi; M-A Dragon-Durey; J Blouin; C Vigneau; D Kuypers; B Boudailliez; C Loirat; E Rondeau; W H Fridman
Journal:  J Med Genet       Date:  2004-06       Impact factor: 6.318

Review 9.  Hemolytic uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

10.  Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease.

Authors:  Jessica Caprioli; Federica Castelletti; Sara Bucchioni; Paola Bettinaglio; Elena Bresin; Gaia Pianetti; Sara Gamba; Simona Brioschi; Erica Daina; Giuseppe Remuzzi; Marina Noris
Journal:  Hum Mol Genet       Date:  2003-10-28       Impact factor: 6.150

View more
  31 in total

1.  Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype.

Authors:  Elena Bresin; Erica Rurali; Jessica Caprioli; Pilar Sanchez-Corral; Veronique Fremeaux-Bacchi; Santiago Rodriguez de Cordoba; Sheila Pinto; Timothy H J Goodship; Marta Alberti; David Ribes; Elisabetta Valoti; Giuseppe Remuzzi; Marina Noris
Journal:  J Am Soc Nephrol       Date:  2013-02-21       Impact factor: 10.121

Review 2.  Links between coagulation, inflammation, regeneration, and fibrosis in kidney pathology.

Authors:  Beatriz Suárez-Álvarez; Helen Liapis; Hans-Joachim Anders
Journal:  Lab Invest       Date:  2016-01-11       Impact factor: 5.662

3.  Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study.

Authors:  Véronique Frémeaux-Bacchi; Anne-Laure Sellier-Leclerc; Paula Vieira-Martins; Sophie Limou; Theresa Kwon; Annie Lahoche; Robert Novo; Brigitte Llanas; François Nobili; Gwenaëlle Roussey; Mathilde Cailliez; Tim Ulinski; Georges Deschênes; Corinne Alberti; François-Xavier Weill; Patricia Mariani; Chantal Loirat
Journal:  Clin J Am Soc Nephrol       Date:  2019-01-23       Impact factor: 8.237

Review 4.  Risk factors and biomarkers of age-related macular degeneration.

Authors:  Nathan G Lambert; Hanan ElShelmani; Malkit K Singh; Fiona C Mansergh; Michael A Wride; Maximilian Padilla; David Keegan; Ruth E Hogg; Balamurali K Ambati
Journal:  Prog Retin Eye Res       Date:  2016-05-06       Impact factor: 21.198

5.  Role of the skin biopsy in the diagnosis of atypical hemolytic uremic syndrome.

Authors:  Cynthia M Magro; Shabnam Momtahen; Joseph Justin Mulvey; Aminah H Yassin; Robert B Kaplan; Jeffrey C Laurence
Journal:  Am J Dermatopathol       Date:  2015-05       Impact factor: 1.533

Review 6.  Genetics and complement in atypical HUS.

Authors:  David Kavanagh; Tim Goodship
Journal:  Pediatr Nephrol       Date:  2010-06-06       Impact factor: 3.714

Review 7.  Anti-complement-factor H-associated glomerulopathies.

Authors:  Marie-Agnes Dragon Durey; Aditi Sinha; Shambhuprasad Kotresh Togarsimalemath; Arvind Bagga
Journal:  Nat Rev Nephrol       Date:  2016-07-25       Impact factor: 28.314

8.  Complement factor H R1210C among Japanese patients with age-related macular degeneration.

Authors:  Masahiro Miyake; Masaaki Saito; Kenji Yamashiro; Tetsuju Sekiryu; Nagahisa Yoshimura
Journal:  Jpn J Ophthalmol       Date:  2015-07-28       Impact factor: 2.447

9.  Dynamics of complement activation in aHUS and how to monitor eculizumab therapy.

Authors:  Marina Noris; Miriam Galbusera; Sara Gastoldi; Paolo Macor; Federica Banterla; Elena Bresin; Claudio Tripodo; Serena Bettoni; Roberta Donadelli; Elisabetta Valoti; Francesco Tedesco; Alessandro Amore; Rosanna Coppo; Piero Ruggenenti; Eliana Gotti; Giuseppe Remuzzi
Journal:  Blood       Date:  2014-07-18       Impact factor: 22.113

10.  Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.

Authors:  Iain Moore; Lisa Strain; Isabel Pappworth; David Kavanagh; Paul N Barlow; Andrew P Herbert; Christoph Q Schmidt; Scott J Staniforth; Lucy V Holmes; Roy Ward; Lynn Morgan; Timothy H J Goodship; Kevin J Marchbank
Journal:  Blood       Date:  2009-10-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.